Theravance Biopharma Q4 Earnings Outlook

Don't be caught off-guard: Theravance Biopharma TBPH releases its next round of earnings Tuesday.

Want to skip the homework and get all the facts in one place? We thought so. Here is your everything-that-matters guide for today's Q4 earnings announcement after the bell.

Earnings and Revenue

Wall Street expects an earnings loss of $1.17 per share and sales around $4.84 million.

Theravance Biopharma EPS in the same period a year ago came in at a loss of $1.36 per share and sales were $5 million. Analysts estimate would represent a 13.97 percent decrease in the company's earnings. Sales would be down 14.97 percent from the year-ago period.

Here's how the company's reported EPS has stacked up against analyst estimates in the past:

Stock Performance

Over the last 52-week period, shares are down 7.54 percent. Given that these returns are generally negative, long-term shareholders won't be happy going into this earnings release. Long-term shareholders are already enjoying 12-month gains prior to the announcement.

Analysts' have adjusted their estimates higher for EPS and revenues over the past 90 days. The popular rating by analysts on Theravance Biopharma stock is a Neutral. The strength of this rating has maintained conviction over the past 90 days.

Conference Call

Theravance's Q4 conference call is scheduled to begin at 5:00 p.m. ET and can be accessed here.